Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

In China, Big Pharma Faces Drug Pricing Pressure

publication date: Jun 1, 2015
Today, June 1, China will end the official caps on most drug prices. Although the administrative change may sound like a major reform, the actual effect will be almost nil. For most drugs in China, most of which are generics, the price is actually set by the province-by-province auctions. By being one of the one or two lowest bidders, a pharma company is allowed to sell its products through hospital pharmacies. However, for multinational pharmas in China, whose premium prices have been protected from the auction process, the situation is quite different. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital